172 related articles for article (PubMed ID: 15358376)
1. Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptide.
Liu Z; Olejniczak ET; Fesik SW
Protein Expr Purif; 2004 Oct; 37(2):493-8. PubMed ID: 15358376
[TBL] [Abstract][Full Text] [Related]
2. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism of the interaction between MDM2 and p53.
Schon O; Friedler A; Bycroft M; Freund SM; Fersht AR
J Mol Biol; 2002 Oct; 323(3):491-501. PubMed ID: 12381304
[TBL] [Abstract][Full Text] [Related]
4. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation.
Leng P; Brown DR; Shivakumar CV; Deb S; Deb SP
Oncogene; 1995 Apr; 10(7):1275-82. PubMed ID: 7731677
[TBL] [Abstract][Full Text] [Related]
5. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.
Shimizu H; Burch LR; Smith AJ; Dornan D; Wallace M; Ball KL; Hupp TR
J Biol Chem; 2002 Aug; 277(32):28446-58. PubMed ID: 11925449
[TBL] [Abstract][Full Text] [Related]
6. The CBP/p300 TAZ1 domain in its native state is not a binding partner of MDM2.
Matt T; Martinez-Yamout MA; Dyson HJ; Wright PE
Biochem J; 2004 Aug; 381(Pt 3):685-91. PubMed ID: 15154850
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW
Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548
[TBL] [Abstract][Full Text] [Related]
8. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.
Liu WL; Midgley C; Stephen C; Saville M; Lane DP
J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
10. Autoinhibition of MDMX by intramolecular p53 mimicry.
Chen L; Borcherds W; Wu S; Becker A; Schonbrunn E; Daughdrill GW; Chen J
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4624-9. PubMed ID: 25825738
[TBL] [Abstract][Full Text] [Related]
11. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.
Popowicz GM; Czarna A; Holak TA
Cell Cycle; 2008 Aug; 7(15):2441-3. PubMed ID: 18677113
[TBL] [Abstract][Full Text] [Related]
12. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding.
Uhrinova S; Uhrin D; Powers H; Watt K; Zheleva D; Fischer P; McInnes C; Barlow PN
J Mol Biol; 2005 Jul; 350(3):587-98. PubMed ID: 15953616
[TBL] [Abstract][Full Text] [Related]
13. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein.
Burch L; Shimizu H; Smith A; Patterson C; Hupp TR
J Mol Biol; 2004 Mar; 337(1):129-45. PubMed ID: 15001357
[TBL] [Abstract][Full Text] [Related]
14. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
[TBL] [Abstract][Full Text] [Related]
15. Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA.
Burch LR; Midgley CA; Currie RA; Lane DP; Hupp TR
FEBS Lett; 2000 Apr; 472(1):93-8. PubMed ID: 10781812
[TBL] [Abstract][Full Text] [Related]
16. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX.
Uldrijan S; Pannekoek WJ; Vousden KH
EMBO J; 2007 Jan; 26(1):102-12. PubMed ID: 17159902
[TBL] [Abstract][Full Text] [Related]
17. Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy.
Shin JS; Ha JH; Chi SW
Biochem Biophys Res Commun; 2014 Jan; 443(3):882-7. PubMed ID: 24342622
[TBL] [Abstract][Full Text] [Related]
18. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2.
Dumaz N; Meek DW
EMBO J; 1999 Dec; 18(24):7002-10. PubMed ID: 10601022
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance.
Kulikov R; Boehme KA; Blattner C
Mol Cell Biol; 2005 Aug; 25(16):7170-80. PubMed ID: 16055726
[TBL] [Abstract][Full Text] [Related]
20. Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53.
Zondlo SC; Lee AE; Zondlo NJ
Biochemistry; 2006 Oct; 45(39):11945-57. PubMed ID: 17002294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
